Beyond glycaemic control, Ozempic can lead to weight loss by reducing appetite and increasing feelings of satiety, although it is not licensed for weight management in the UK (Wegovy is the licensed semaglutide product for weight management)
The cagrilintide and semaglutide combination targets both GLP-1 and amylin pathways simultaneously
Still, with proven results, its clear why GLP-1 medications are being viewed as a significant breakthrough for people dealing with obesity and struggling with weight loss
Given potential confounding in observational studies, the causality between GLP1RAs and COPD, as well as related diseases, needs further elucidation [18, 19]
This is reported context, not a recommendation
One possible side effect that concerns some people is heart palpitations , which are feelings of a racing or irregular heartbeat